Clinical Research Directory

Inclusion Criteria: * T1D treated with intensive insulin therapy (multiple daily insulin injections or continuous subcutaneous insulin infusion systems) * HbA1c 6.5-9% * BMI ≥ 25 and ≤ 45 kg/m2 * Active prescription and use of CGM * Active prescription for glucagon Exclusion Criteria: * Pregnancy, pregnancy planning, or breastfeeding * Forms of diabetes other than T1D, or T1D duration \< 1 year * Previous cardiovascular events (acute myocardial infarction or stroke), heart failure, unstable coronary artery disease, chronic kidney disease with estimated glomerular filtration rate ≤ 30 mL/min/m², cirrhosis, or presence of active cancer * Unstable diabetes, episodes of glycemic decompensation (diabetic ketoacidosis) or severe hypoglycemia (level 3) within the past year. * Planned change in treatment during the study (switching from multiple daily insulin injections to continuous insulin infusion, or vice versa) * Use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, GLP-1/GIP agonists, or other medications that may influence weight loss * Having experienced a change in body weight greater than 5% within the 3 months before screening * Following any form of diet prior to inclusion, carbohydrate restriction, or intermittent fasting * History of eating disorders or alcohol abuse * Inability to follow the dietary recommendations * Presence of other conditions that, in the investigator's judgment, may compromise participation in the study.